Spots Global Cancer Trial Database for squamous cell carcinoma of the head and neck (scchn)
Every month we try and update this database with for squamous cell carcinoma of the head and neck (scchn) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of ASP1951 in Subjects With Advanced Solid Tumors | NCT03799003 | Advanced Solid ... | ASP1951 pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| Study of PX-866 and Docetaxel in Solid Tumors | NCT01204099 | Non Small Cell ... Squamous Cell C... | Docetaxel PX-866 | 18 Years - | Seagen Inc. | |
| Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer | NCT03405142 | Head and Neck S... Squamous Cell C... Head and Neck C... | Panitumumab-IRD... Lymphoseek | 19 Years - | Stanford University | |
| Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies | NCT05577182 | Advanced Malign... | INCA32459-101 | 18 Years - | Incyte Corporation | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| A Study of ASP1951 in Subjects With Advanced Solid Tumors | NCT03799003 | Advanced Solid ... | ASP1951 pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | NCT02988960 | Advanced Solid ... | ABBV-927 ABBV-927 ABBV-181 | 18 Years - | AbbVie | |
| Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | NCT03174275 | Carcinoma, Squa... Oral Cancer Oropharynx Canc... Larynx Cancer Lip Cancer Esophageal Canc... | Durvalumab Carboplatin Nab-paclitaxel Cisplatin Surgical resect... IMRT | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | NCT03565445 | Advanced Solid ... | ASP1948 nivolumab pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | NCT02001623 | Ovary Cancer Cervix Cancer Endometrium Can... Bladder Cancer Prostate Cancer... Esophagus Cance... Lung Cancer(NSC... Squamous Cell C... | Tisotumab Vedot... | 18 Years - | Seagen Inc. | |
| A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | NCT02335918 | Squamous Cell C... Ovarian Carcino... Colorectal Canc... Renal Cell Carc... Glioblastoma (G... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | NCT02001623 | Ovary Cancer Cervix Cancer Endometrium Can... Bladder Cancer Prostate Cancer... Esophagus Cance... Lung Cancer(NSC... Squamous Cell C... | Tisotumab Vedot... | 18 Years - | Seagen Inc. | |
| A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | NCT03361228 | Solid Tumors | INCB001158 Epacadostat Pembrolizumab | 18 Years - | Incyte Corporation | |
| Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | NCT02499120 | Squamous Cell C... | palbociclib Cetuximab Placebo | 18 Years - | Pfizer | |
| A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | NCT04943900 | Advanced Solid ... | BMS-986416 Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | NCT03347123 | Solid Tumors | Epacadostat Nivolumab Ipilimumab Lirilumab | 18 Years - | Incyte Corporation | |
| Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT05287113 | Head and Neck C... | Retifanlimab INCAGN02385 INCAGN02390 Placebo | 18 Years - 99 Years | Incyte Corporation | |
| Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT05287113 | Head and Neck C... | Retifanlimab INCAGN02385 INCAGN02390 Placebo | 18 Years - 99 Years | Incyte Corporation | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | NCT00392665 | Squamous Cell C... | Bevacizumab erlotinib Sulindac | 18 Years - | Massachusetts General Hospital | |
| Study of PX-866 and Docetaxel in Solid Tumors | NCT01204099 | Non Small Cell ... Squamous Cell C... | Docetaxel PX-866 | 18 Years - | Seagen Inc. | |
| INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | NCT03277352 | Advanced Malign... Metastatic Canc... | INCAGN01876 Epacadostat Pembrolizumab | 18 Years - | Incyte Corporation | |
| Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC | NCT05057247 | Squamous Cell C... Recurrent Squam... Metastatic Head... Advanced Head a... Advanced Head a... | Duvelisib Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck | NCT01285635 | Squamous Cell C... | AT-101 Docetaxel | 18 Years - | University of Michigan Rogel Cancer Center | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer | NCT03405142 | Head and Neck S... Squamous Cell C... Head and Neck C... | Panitumumab-IRD... Lymphoseek | 19 Years - | Stanford University | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
